Current Report Filing (8-k)
October 08 2019 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
October 8, 2019
|
INMUNE BIO INC.
|
|
|
(Exact name of registrant as specified in charter)
|
|
Nevada
|
|
001-38793
|
|
47-5205835
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(IRS Employer
|
of incorporation)
|
|
|
|
Identification No.)
|
1200 Prospect Street, Suite 525 La Jolla,
CA 92037
(Address of Principal Executive Offices) (Zip
Code)
(858) 964 3720
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, If Changed Since
Last Report)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
INMB
|
|
NASDAQ
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On October 8, 2019, INmune
Bio, Inc. (the “Company”) published a press release (the “Press Release”) announcing that RJ Tesi, M.D.,
Co-Founder and CEO will present at the 2nd Annual Advances in Immuno-Oncology USA Congress in San Diego taking place on October
8 and October 9, 2019, and that Dr. Tesi and CJ Barnum, Ph.D., Director of Neuroscience for the Company, will also present at the
World Immunotherapy Congress taking place in Basel Switzerland from October 15 through October 17, 2019.
A copy of the Press Release
is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Exhibits 99.1 shall not be deemed “filed” for
purposed of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject
to the liabilities under that Section and shall not be deemed to be incorporated into any filing of the Company under the Securities
Act of 1933, as amended, or the Exchange Act.
Item 9.01 Financial statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
INMUNE BIO INC.
|
|
|
Date: October 8, 2019
|
By:
|
/s/ David Moss
|
|
|
David Moss
|
|
|
Chief Financial Officer
|
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Sep 2023 to Sep 2024